485 related articles for article (PubMed ID: 28433750)
1. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide.
Morsi N; Ibrahim M; Refai H; El Sorogy H
Eur J Pharm Sci; 2017 Jun; 104():302-314. PubMed ID: 28433750
[TBL] [Abstract][Full Text] [Related]
2. Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide.
Bhalerao H; Koteshwara KB; Chandran S
Drug Deliv Transl Res; 2020 Apr; 10(2):529-547. PubMed ID: 31820300
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies.
Ranch KM; Maulvi FA; Naik MJ; Koli AR; Parikh RK; Shah DO
Int J Pharm; 2019 Jan; 554():264-275. PubMed ID: 30423418
[TBL] [Abstract][Full Text] [Related]
4. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
Singh J; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
[TBL] [Abstract][Full Text] [Related]
5. Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation.
Kouchak M; Mahmoodzadeh M; Farrahi F
AAPS PharmSciTech; 2019 Jun; 20(5):210. PubMed ID: 31161269
[TBL] [Abstract][Full Text] [Related]
6. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.
Destruel PL; Zeng N; Seguin J; Douat S; Rosa F; Brignole-Baudouin F; Dufaÿ S; Dufaÿ-Wojcicki A; Maury M; Mignet N; Boudy V
Int J Pharm; 2020 Jan; 574():118734. PubMed ID: 31705970
[TBL] [Abstract][Full Text] [Related]
7. L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations.
Singh SR; Carreiro ST; Chu J; Prasanna G; Niesman MR; Collette Iii WW; Younis HS; Sartnurak S; Gukasyan HJ
J Pharm Pharmacol; 2009 Jun; 61(6):733-42. PubMed ID: 19505363
[TBL] [Abstract][Full Text] [Related]
8. Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration.
Salunke SR; Patil SB
Int J Biol Macromol; 2016 Jun; 87():41-7. PubMed ID: 26899173
[TBL] [Abstract][Full Text] [Related]
9. Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation.
Bhalerao H; Koteshwara KB; Chandran S
AAPS PharmSciTech; 2020 Jan; 21(2):69. PubMed ID: 31950311
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.
Rupenthal ID; Green CR; Alany RG
Int J Pharm; 2011 Jun; 411(1-2):69-77. PubMed ID: 21453762
[TBL] [Abstract][Full Text] [Related]
11. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
12. A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation.
Sun J; Zhou Z
Drug Des Devel Ther; 2018; 12():383-389. PubMed ID: 29503531
[TBL] [Abstract][Full Text] [Related]
13. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.
Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH
Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217
[TBL] [Abstract][Full Text] [Related]
14. Investigating the ability of nanoparticle-loaded hydroxypropyl methylcellulose and xanthan gum gels to enhance drug penetration into the skin.
Cai XJ; Mesquida P; Jones SA
Int J Pharm; 2016 Nov; 513(1-2):302-308. PubMed ID: 27576666
[TBL] [Abstract][Full Text] [Related]
15. A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation.
Zhu L; Ao J; Li P
Drug Des Devel Ther; 2015; 9():3943-9. PubMed ID: 26251573
[TBL] [Abstract][Full Text] [Related]
16. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
Rupenthal ID; Green CR; Alany RG
Int J Pharm; 2011 Jun; 411(1-2):78-85. PubMed ID: 21453763
[TBL] [Abstract][Full Text] [Related]
18. Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3
Barse RK; Tagalpallewar AA; Kokare CR; Sharma JP; Sharma PK
Drug Dev Ind Pharm; 2018 May; 44(5):800-807. PubMed ID: 29228819
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment.
El-Feky YA; Fares AR; Zayed G; El-Telbany RFA; Ahmed KA; El-Telbany DFA
Biomed Pharmacother; 2021 Oct; 142():112008. PubMed ID: 34385102
[TBL] [Abstract][Full Text] [Related]
20. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits.
Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA
Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
